Literature DB >> 20139701

Chromosomal and genomic changes in lung cancer.

Marileila Varella-Garcia1.   

Abstract

Lung cancer is a complex spectrum of diseases characterized by extensive genomic instability, which can be detected among both histological subtypes and different foci within a tumor. Conventional and cutting edge investigative technologies have uncovered scores of genomic changes in individual specimens that have been used to characterize specific molecular subtypes. Oncogenes with predominant roles in lung cancer include EGFR, MYC and RAS family members, PIK3CA, NKX2-1 and ALK; tumor suppressor genes include TP53, RB1, CDKN2, and a cluster of genes mapped at 3p. MicroRNA regulators also have been linked to lung cancer. The functional role of the recurrent genomic changes in lung tumors has been explored, which has led to a better understanding of cell growth, differentiation and apoptotic pathways. Additionally, this knowledge has supported the development of novel therapeutics and translational tools for selection of patients for personalized therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20139701      PMCID: PMC2852566          DOI: 10.4161/cam.4.1.10884

Source DB:  PubMed          Journal:  Cell Adh Migr        ISSN: 1933-6918            Impact factor:   3.405


  90 in total

1.  Matrix-based comparative genomic hybridization: biochips to screen for genomic imbalances.

Authors:  S Solinas-Toldo; S Lampel; S Stilgenbauer; J Nickolenko; A Benner; H Döhner; T Cremer; P Lichter
Journal:  Genes Chromosomes Cancer       Date:  1997-12       Impact factor: 5.006

2.  Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.

Authors:  Federico Cappuzzo; Fred R Hirsch; Elisa Rossi; Stefania Bartolini; Giovanni L Ceresoli; Lynne Bemis; Jerry Haney; Samir Witta; Kathleen Danenberg; Irene Domenichini; Vienna Ludovini; Elisabetta Magrini; Vanesa Gregorc; Claudio Doglioni; Angelo Sidoni; Maurizio Tonato; Wilbur A Franklin; Lucio Crino; Paul A Bunn; Marileila Varella-Garcia
Journal:  J Natl Cancer Inst       Date:  2005-05-04       Impact factor: 13.506

3.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis.

Authors:  Nozomu Yanaihara; Natasha Caplen; Elise Bowman; Masahiro Seike; Kensuke Kumamoto; Ming Yi; Robert M Stephens; Aikou Okamoto; Jun Yokota; Tadao Tanaka; George Adrian Calin; Chang-Gong Liu; Carlo M Croce; Curtis C Harris
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

4.  Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers.

Authors:  George Adrian Calin; Cinzia Sevignani; Calin Dan Dumitru; Terry Hyslop; Evan Noch; Sai Yendamuri; Masayoshi Shimizu; Sashi Rattan; Florencia Bullrich; Massimo Negrini; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-18       Impact factor: 11.205

5.  High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays.

Authors:  D Pinkel; R Segraves; D Sudar; S Clark; I Poole; D Kowbel; C Collins; W L Kuo; C Chen; Y Zhai; S H Dairkee; B M Ljung; J W Gray; D G Albertson
Journal:  Nat Genet       Date:  1998-10       Impact factor: 38.330

6.  Specific chromosome defect associated with human small-cell lung cancer; deletion 3p(14-23).

Authors:  J Whang-Peng; C S Kao-Shan; E C Lee; P A Bunn; D N Carney; A F Gazdar; J D Minna
Journal:  Science       Date:  1982-01-08       Impact factor: 47.728

7.  Mutational analysis of the BRAF gene in human tumor cells.

Authors:  Masatsugu Ueda; Eisaku Toji; Osamu Nunobiki; Shinji Izuma; Yoshiaki Okamoto; Kiyo Torii; Sadamu Noda
Journal:  Hum Cell       Date:  2008-05       Impact factor: 4.174

8.  A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy.

Authors:  Enriqueta Felip; Federico Rojo; Martin Reck; Astrid Heller; Barbara Klughammer; Gemma Sala; Susana Cedres; Sergio Peralta; Heiko Maacke; Dorothee Foernzler; Marta Parera; Joachim Möcks; Cristina Saura; Ulrich Gatzemeier; José Baselga
Journal:  Clin Cancer Res       Date:  2008-06-15       Impact factor: 12.531

9.  KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.

Authors:  Erminia Massarelli; Marileila Varella-Garcia; Ximing Tang; Ana C Xavier; Natalie C Ozburn; Diane D Liu; Benjamin N Bekele; Roy S Herbst; Ignacio I Wistuba
Journal:  Clin Cancer Res       Date:  2007-05-15       Impact factor: 12.531

10.  Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

Authors:  Klarisa Rikova; Ailan Guo; Qingfu Zeng; Anthony Possemato; Jian Yu; Herbert Haack; Julie Nardone; Kimberly Lee; Cynthia Reeves; Yu Li; Yerong Hu; Zhiping Tan; Matthew Stokes; Laura Sullivan; Jeffrey Mitchell; Randy Wetzel; Joan Macneill; Jian Min Ren; Jin Yuan; Corey E Bakalarski; Judit Villen; Jon M Kornhauser; Bradley Smith; Daiqiang Li; Xinmin Zhou; Steven P Gygi; Ting-Lei Gu; Roberto D Polakiewicz; John Rush; Michael J Comb
Journal:  Cell       Date:  2007-12-14       Impact factor: 41.582

View more
  16 in total

1.  Chromosome 7 Multiplication in EGFR-positive Lung Carcinomas Based on Tissue Microarray Analysis.

Authors:  Evangelos Tsiambas; Nicholas S Mastronikolis; Alicia Y Lefas; Stavros N Georgiannos; Vasileios Ragos; Panagiotis P Fotiades; Nikolaos Tsoukalas; Nikolaos Kavantzas; Andreas Karameris; Dimitrios Peschos; Efstratios Patsouris; Konstantinos Syrigos
Journal:  In Vivo       Date:  2017 Jul-Aug       Impact factor: 2.155

Review 2.  [DNA Damage Repair System and Antineoplastic Agents in Lung Cancer].

Authors:  Linlin Zhang; Fanlu Meng; Diansheng Zhong
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2022-06-20

3.  Prognostic Significance of the Loss of Heterozygosity of KRAS in Early-Stage Lung Adenocarcinoma.

Authors:  Anand Khadse; Vilde D Haakensen; Laxmi Silwal-Pandit; Julian Hamfjord; Patrick Micke; Johan Botling; Odd Terje Brustugun; Ole Christian Lingjærde; Åslaug Helland; Elin H Kure
Journal:  Front Oncol       Date:  2022-04-29       Impact factor: 5.738

Review 4.  Revisiting tumour aneuploidy - the place of ploidy assessment in the molecular era.

Authors:  Håvard E Danielsen; Manohar Pradhan; Marco Novelli
Journal:  Nat Rev Clin Oncol       Date:  2015-11-24       Impact factor: 66.675

Review 5.  Small-cell lung cancer: what we know, what we need to know and the path forward.

Authors:  Adi F Gazdar; Paul A Bunn; John D Minna
Journal:  Nat Rev Cancer       Date:  2017-10-27       Impact factor: 60.716

6.  Neoplastic-like transformation effect of single-walled and multi-walled carbon nanotubes compared to asbestos on human lung small airway epithelial cells.

Authors:  Liying Wang; Todd A Stueckle; Anurag Mishra; Raymond Derk; Terence Meighan; Vincent Castranova; Yon Rojanasakul
Journal:  Nanotoxicology       Date:  2013-05-28       Impact factor: 5.913

7.  Chromosomal and Genetic Analysis of a Human Lung Adenocarcinoma Cell Line OM.

Authors:  Yong-Wu Li; Lin Bai; Lyu-Xia Dai; Xu He; Xian-Ping Zhou
Journal:  Chin Med J (Engl)       Date:  2016-02-20       Impact factor: 2.628

Review 8.  The potential of exploiting DNA-repair defects for optimizing lung cancer treatment.

Authors:  Sophie Postel-Vinay; Elsa Vanhecke; Ken A Olaussen; Christopher J Lord; Alan Ashworth; Jean-Charles Soria
Journal:  Nat Rev Clin Oncol       Date:  2012-02-14       Impact factor: 66.675

9.  LACES and bootstraps: the hunt for prognostic and predictive markers for adjuvant therapy in NSCLC.

Authors:  Rachael Chang Lee; Bibhusal Thapa; Thomas John
Journal:  Transl Lung Cancer Res       Date:  2018-09

Review 10.  DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy.

Authors:  Ruixue Huang; Ping-Kun Zhou
Journal:  Signal Transduct Target Ther       Date:  2021-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.